2-胺-5-溴-3-硝苯甲酸 | 58580-07-7

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-胺-5-溴-3-硝苯甲酸
• 中文别名: 2-胺-5-溴-3-硝苄酸
• 英文名称: 2-amino-5-bromo-3-nitrobenzoic acid
• CAS: 58580-07-7
• 化学式: C₇H₅BrN₂O₄
• mdl: MFCD09970266
• 分子量: 261.032
• InChiKey: MCQLFDJHSKKLHC-UHFFFAOYSA-N

物化性质

• 熔点：
  245-247℃
• 沸点：
  401.1±45.0 °C(Predicted)
• 密度：
  1.973±0.06 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  2-胺-5-溴-3-硝苯甲酸 在 sodium dithionite 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 N-(2-amino-5-bromo-3-carbamoyl-phenyl)pyridine-4-carboxamide
  参考文献：
  名称：

  Development of 2-(4-pyridyl)-benzimidazoles as PKN2 chemical tools to probe cancer

  摘要：

  Kinases are signalling proteins which have proven to be successful targets for the treatment of a variety of diseases, predominantly in cancers. However, only a small proportion of kinases ( < 20%) have been investigated for their therapeutic viability, likely due to the lack of available chemical tools across the kinome. In this work we describe initial efforts in the development of a selective chemical tool for protein kinase N2 (PKN2), a relatively unexplored kinase of interest in several types of cancer. The most successful compound, 5, has a measured IC50 of 0.064 mu M against PKN2, with ca. 17-fold selectivity over close homologue, PKN1.

  DOI：

  10.1016/j.bmcl.2020.127040
• 作为产物：
  描述：

  5-溴-7-硝基吲哚啉-2,3-二酮 在 双氧水 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 4.0h， 以96%的产率得到2-胺-5-溴-3-硝苯甲酸
  参考文献：
  名称：

  [EN] 1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS
  [FR] DÉRIVÉS DE 1, 4, 6-TRISUBSTITUÉ-2-ALKYL-1H-BENZO[D]IMIDAZOLE EN TANT QU'INHIBITEURS DE DIHYDROOROTATE OXYGÉNASE

  摘要：

  本发明提供了作为脱氢鸟苷酸氧化酶抑制剂的化合物的1,4,6-三取代-2-烷基-1H-苯并[d]咪唑衍生物，其化学式为(I)，可能在治疗中有用作DHODH抑制剂，其中R1到R3和'm'在说明书中给出了相应的含义，以及在治疗和预防疾病或疾病中有用的药学上可接受的盐或立体异构体，特别是在抑制DHODH方面具有优势的疾病或疾病的使用。本发明还提供了合成化合物1,4,6-三取代-2-烷基-1H-苯并[d]咪唑的方法(I)。本发明还提供了包含化合物(I)中至少一种DHODH抑制剂与药学上可接受的载体、稀释剂或赋形剂的制剂。

  公开号：

  WO2018154088A1

文献信息

• [EN] SUBSTITUTED QUINOXALINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOXALINE SUBSTITUÉS
  申请人：SELVITA S A

  公开号：WO2016180536A1

  公开（公告）日：2016-11-17

  The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

  本发明涉及取代喹喔啉衍生物。这些化合物对预防和/或治疗包括过度增殖性疾病在内的多种医疗状况具有用处。
• Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
  申请人：——

  公开号：US20020049327A1

  公开（公告）日：2002-04-25

  This invention concerns compounds of formula 1 the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; -A- is a bivalent radical of formula; R 1 and R 2 each independently are hydrogen, hydroxy, halo, cyano, C 1-6 alkyl, trihalomethyl, trihalomethoxy, C 2-6 alkenyl, C 1-6 alkyloxy, hydroxyC 1-6 alkyloxy, C 1-6 alkyloxyC 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, aminoC 1-6 alkyloxy, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyloxy, Ar, Ar—C 1-6 alkyl, Ar-oxy, Ar—C 1-6 alkyloxy; or when on adjacent positions R 1 and R 2 taken together may form a bivalent radical; R 3 and R 4 each independently are hydrogen, halo, cyano, C 1-6 alkyl, C 1-6 alkyloxy, Ar-oxy, C 1-6 alkylthio, di(C 1-6 alkyl)amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R 3 and R 4 taken together may form a bivalent radical; R 5 is an imidazolyl substituted with hydrogen or C 1-6 alkyl; R 6 hydrogen, hydroxy, halo, cyano, optionally substituted C 1-6 alkyl, C 1-6 alkyloxycarbonyl or Ar; or a radical of formula —O—R 7 , —S—R 8 , —N—R 8 R 9 ; and Ar is optionally substituted phenyl; having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.

  本发明涉及公式1的化合物及其药物可接受的酸盐和立体化学异构体，其中虚线表示可选键；X是氧或硫；-A-是公式的二价基团；R1和R2各自独立地是氢、羟基、卤、氰、C1-6烷基、三卤甲基、三卤甲氧基、C2-6烯基、C1-6烷氧基、羟基C1-6烷氧基、C1-6烷氧基C1-6烷氧基、C1-6烷氧羰基、氨基C1-6烷氧基、单烷基或二烷基氨基C1-6烷氧基、Ar、Ar-C1-6烷基、Ar-oxy、Ar-C1-6烷氧基；或当相邻位置的R1和R2一起形成二价基团时；R3和R4各自独立地是氢、卤、氰、C1-6烷基、C1-6烷氧基、Ar-oxy、C1-6烷硫基、二(C1-6烷基)氨基、三卤甲基、三卤甲氧基；或当相邻位置的R3和R4一起形成二价基团时；R5是氢或C1-6烷基取代的咪唑基；R6是氢、羟基、卤、氰、可选取代的C1-6烷基、C1-6烷氧羰基或Ar；或公式-O-R7、-S-R8、-N-R8R9的基团；Ar是可选取代的苯基；具有法尼酰转移酶抑制活性；它们的制备、含有它们的组合物以及它们作为药物的用途。
• Intermediate compounds in the preparation of farnnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N-or C linked imidazoles
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06444812B1

  公开（公告）日：2002-09-03

  This invention concerns intermediates in the preparation of compounds of formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; —A— is a bivalent radical of formula; R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar, Ar—C1-6alkyl, Ar-oxy, Ar—C1-6alkyloxy; or when on adjacent positions R1 and R2 taken together may form a bivalent radical; R3 and R4 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar-oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R3 and R4 taken together may form a bivalent radical; R5 is an imidazolyl substituted with hydrogen or C1-6alkyl; R6 hydrogen, hydroxy, halo, cyano, optionally substituted C1-6alkyl, C1-6alkyloxycarbonyl or Ar; or a radical of formula —O—R7, —S—R8, —N—R8R9; and Ar is optionally substituted phenyl; and of the preparation, thereof.

  本发明涉及制备公式化合物的中间体，其药学上可接受的酸加成盐和其立体化学异构体，其中点线表示可选的键；X为氧或硫；-A-为公式的二价基团；R1和R2各自独立地为氢、羟基、卤素、氰基、C1-6烷基、三卤甲基、三卤甲氧基、C2-6烯基、C1-6烷氧基、羟基C1-6烷氧基、C1-6烷氧基C1-6烷氧基、C1-6烷氧羰基、氨基C1-6烷氧基、单烷基或双(C1-6烷基)氨基C1-6烷氧基、Ar、Ar-C1-6烷基、Ar氧基、Ar-C1-6烷氧基；或当相邻的R1和R2共同形成二价基团时；R3和R4各自独立地为氢、卤素、氰基、C1-6烷基、C1-6烷氧基、Ar氧基、C1-6烷基硫基、双(C1-6烷基)氨基、三卤甲基、三卤甲氧基；或当相邻的R3和R4共同形成二价基团时；R5为氢或C1-6烷基取代的咪唑基；R6为氢、羟基、卤素、氰基、可选取代的C1-6烷基、C1-6烷氧羰基或Ar；或为公式-O-R7、-S-R8、-N-R8R9的基团；Ar为可选取代的苯基；以及其制备方法。
• DIHYDROOROTATE DEHYDROGENASE INHIBITORS
  申请人：Thunuguntla Siva Sanjeeva Rao

  公开号：US20120028959A1

  公开（公告）日：2012-02-02

  The invention relates to compounds of formula (I) wherein R 1 , R 2 , X 1 , X 2 , Y, R a , R b , Q have the meanings given in claim 1 . The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

  本发明涉及式(I)的化合物，其中R1、R2、X1、X2、Y、Ra、Rb、Q的含义如权利要求书所述。该化合物在治疗自身免疫性疾病，如多发性硬化症，以及治疗癌症方面具有有用性。
• Dihydroorotate dehydrogenase inhibitors
  申请人：Thunuguntla Siva Sanjeeva Rao

  公开号：US09006454B2

  公开（公告）日：2015-04-14

  The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

  本发明涉及式（I）的化合物，其中R1，R2，X1，X2，Y，Ra，Rb，Q具有权利要求书1中给出的含义。这些化合物可用于治疗自身免疫性疾病，如多发性硬化症，也可用于治疗癌症等疾病。